1. Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety).
- Author
-
Federle MP, Chezmar JL, Rubin DL, Weinreb JC, Freeny PC, Semelka RC, Brown JJ, Borello JA, Lee JK, Mattrey R, Dachman AH, Saini S, Harmon B, Fenstermacher M, Pelsang RE, Harms SE, Mitchell DG, Halford HH, Anderson MW, Johnson CD, Francis IR, Bova JG, Kenney PJ, Klippenstein DL, Foster GS, and Turner DA
- Subjects
- Abdominal Pain chemically induced, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases chemically induced, Contrast Media adverse effects, Diagnosis, Differential, Edetic Acid adverse effects, Female, Humans, Injections, Intravenous adverse effects, Male, Middle Aged, Pain etiology, Pregnancy, Pyridoxal Phosphate adverse effects, Risk Assessment, Sensitivity and Specificity, Vomiting chemically induced, Edetic Acid analogs & derivatives, Image Enhancement methods, Liver Cirrhosis diagnosis, Liver Neoplasms diagnosis, Magnetic Resonance Imaging methods, Pyridoxal Phosphate analogs & derivatives
- Abstract
The short-term safety of mangafodipir trisodium (MnDPDP) injection was studied in 546 adults with known or suspected focal liver lesions. An initial contrast-enhanced computed tomography examination was followed by unenhanced magnetic resonance imaging (MRI), injection of MnDPDP (5 micromol/kg), and enhanced MRI. Adverse events were reported for 23% of the patients; most were mild to moderate in intensity, did not require treatment, and were not drug related. The most commonly reported adverse events were nausea (7%) and headache (4%). The incidence of serious adverse events was low (nine events in six patients) and not drug related. Injection-associated discomfort was reported for 69% of the patients, and the most commonly reported discomforts included heat (49%) and flushing (33%). Changes in laboratory values and vital signs were generally transient, were not clinically significant, and did not require treatment. There were no clinically significant short-term risks from exposure to MnDPDP.
- Published
- 2000
- Full Text
- View/download PDF